Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy.

Autor: Wienke J; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. Electronic address: j.wienke-4@prinsesmaximacentrum.nl., Visser LL; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Kholosy WM; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Keller KM; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Barisa M; Cancer Section, Developmental Biology and Cancer Programme, UCL Great Ormond Street Institute of Child Health, London, UK., Poon E; Division of Clinical Studies, The Institute of Cancer Research, London, UK., Munnings-Tomes S; Cancer Section, Developmental Biology and Cancer Programme, UCL Great Ormond Street Institute of Child Health, London, UK., Himsworth C; Cancer Section, Developmental Biology and Cancer Programme, UCL Great Ormond Street Institute of Child Health, London, UK., Calton E; Division of Clinical Studies, The Institute of Cancer Research, London, UK., Rodriguez A; Hoffman-La Roche, Basel, Switzerland., Bernardi R; Genentech, A Member of the Roche Group, South San Francisco, CA, USA., van den Ham F; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., van Hooff SR; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Matser YAH; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Tas ML; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Langenberg KPS; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Lijnzaad P; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Borst AL; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Zappa E; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Bergsma FJ; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Strijker JGM; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Verhoeven BM; Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden., Mei S; Department of Biomedical Informatics, Harvard Medical School, Boston, MA 02115, USA., Kramdi A; Institut Curie, Inserm U830, PSL Research University, Diversity and Plasticity of Childhood Tumors Lab, Paris, France; SIREDO: Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, Paris, France., Restuadi R; Infection, Immunity and Inflammation Research and Teaching Department, UCL Great Ormond Street Institute of Child Health, London, UK; NIHR Biomedical Research Centre, Great Ormond Street Hospital, London, UK., Sanchez-Bernabeu A; Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands; Netherlands Proteomics Centre, Utrecht University, Utrecht, the Netherlands., Cornel AM; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Center for Translational Immunology, University Medical Center Utrecht, Utrecht, the Netherlands., Holstege FCP; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Gray JC; Centre for Cancer Immunology, University of Southampton, Southampton, UK., Tytgat GAM; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Scheijde-Vermeulen MA; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Wijnen MHWA; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Dierselhuis MP; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Straathof K; University College London (UCL) Great Ormond Street Institute of Child Health, London, UK; UCL Cancer Institute, London, UK., Behjati S; Wellcome Sanger Institute, Hinxton, UK; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Department of Paediatrics, University of Cambridge, Cambridge, UK., Wu W; Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands; Netherlands Proteomics Centre, Utrecht University, Utrecht, the Netherlands; Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A∗STAR), Singapore, Singapore; Department of Pharmacy, National University of Singapore, Singapore, Singapore., Heck AJR; Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands; Netherlands Proteomics Centre, Utrecht University, Utrecht, the Netherlands., Koster J; Amsterdam UMC location University of Amsterdam, Center for Experimental and Molecular Medicine, Amsterdam, the Netherlands., Nierkens S; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Center for Translational Immunology, University Medical Center Utrecht, Utrecht, the Netherlands., Janoueix-Lerosey I; Institut Curie, Inserm U830, PSL Research University, Diversity and Plasticity of Childhood Tumors Lab, Paris, France; SIREDO: Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, Paris, France., de Krijger RR; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands., Baryawno N; Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden., Chesler L; Division of Clinical Studies, The Institute of Cancer Research, London, UK., Anderson J; Cancer Section, Developmental Biology and Cancer Programme, UCL Great Ormond Street Institute of Child Health, London, UK; Department of Oncology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, England, UK., Caron HN; Hoffman-La Roche, Basel, Switzerland., Margaritis T; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., van Noesel MM; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Division Imaging & Cancer, University Medical Center Utrecht, Utrecht, the Netherlands., Molenaar JJ; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Department of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.

Publikováno v: Cancer cell [Cancer Cell] 2024 Feb 12; Vol. 42 (2), pp. 283-300.e8. Date of Electronic Publication: 2024 Jan 04.

Simple, fast and efficient iTOP-mediated delivery of CRISPR/Cas9 RNP in difficult-to-transduce human cells including primary T cells.

Autor: Kholosy WM; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, the Netherlands., Visscher M; NTrans Technologies BV, Heidelberglaan 7, 3584 CS Utrecht, the Netherlands., Ogink K; NTrans Technologies BV, Heidelberglaan 7, 3584 CS Utrecht, the Netherlands., Buttstedt H; NTrans Technologies BV, Heidelberglaan 7, 3584 CS Utrecht, the Netherlands., Griffin K; NTrans Technologies BV, Heidelberglaan 7, 3584 CS Utrecht, the Netherlands., Beier A; KNAW-Hubrecht Institute, Uppsalalaan 8, 3584 CT Utrecht, the Netherlands., Gerlach JP; NTrans Technologies BV, Heidelberglaan 7, 3584 CS Utrecht, the Netherlands., Molenaar JJ; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, the Netherlands., Geijsen N; KNAW-Hubrecht Institute, Uppsalalaan 8, 3584 CT Utrecht, the Netherlands., de Boer M; NTrans Technologies BV, Heidelberglaan 7, 3584 CS Utrecht, the Netherlands., Chatsisvili A; NTrans Technologies BV, Heidelberglaan 7, 3584 CS Utrecht, the Netherlands. Electronic address: a.chatsisvili@uu.nl.

Publikováno v: Journal of biotechnology [J Biotechnol] 2021 Sep 10; Vol. 338, pp. 71-80. Date of Electronic Publication: 2021 Jul 13.

Tumor to normal single-cell mRNA comparisons reveal a pan-neuroblastoma cancer cell.

Autor: Kildisiute G; Wellcome Sanger Institute, CB10 1SA Hinxton, UK., Kholosy WM; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, Netherlands., Young MD; Wellcome Sanger Institute, CB10 1SA Hinxton, UK. my4@sanger.ac.uk k.straathof@ucl.ac.uk j.j.molenaar@prinsesmaximacentrum.nl sb31@sanger.ac.uk., Roberts K; Wellcome Sanger Institute, CB10 1SA Hinxton, UK., Elmentaite R; Wellcome Sanger Institute, CB10 1SA Hinxton, UK., van Hooff SR; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, Netherlands., Pacyna CN; Wellcome Sanger Institute, CB10 1SA Hinxton, UK., Khabirova E; Wellcome Sanger Institute, CB10 1SA Hinxton, UK., Piapi A; UCL Great Ormond Street Institute of Child Health, WC1N 1EH London, UK., Thevanesan C; UCL Great Ormond Street Institute of Child Health, WC1N 1EH London, UK., Bugallo-Blanco E; UCL Great Ormond Street Institute of Child Health, WC1N 1EH London, UK., Burke C; UCL Great Ormond Street Institute of Child Health, WC1N 1EH London, UK., Mamanova L; Wellcome Sanger Institute, CB10 1SA Hinxton, UK., Keller KM; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, Netherlands., Langenberg-Ververgaert KPS; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, Netherlands., Lijnzaad P; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, Netherlands., Margaritis T; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, Netherlands., Holstege FCP; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, Netherlands., Tas ML; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, Netherlands., Wijnen MHWA; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, Netherlands., van Noesel MM; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, Netherlands., Del Valle I; UCL Great Ormond Street Institute of Child Health, WC1N 1EH London, UK., Barone G; Great Ormond Street Hospital for Children (GOSH), NHS Foundation Trust, NIHR Great Ormond Street Hospital Biomedical Research Centre, WC1N 3JH London, UK., van der Linden R; Hubrecht Institute, KNAW, 3584 CT Utrecht, Netherlands., Duncan C; Great Ormond Street Hospital for Children (GOSH), NHS Foundation Trust, NIHR Great Ormond Street Hospital Biomedical Research Centre, WC1N 3JH London, UK., Anderson J; UCL Great Ormond Street Institute of Child Health, WC1N 1EH London, UK.; Great Ormond Street Hospital for Children (GOSH), NHS Foundation Trust, NIHR Great Ormond Street Hospital Biomedical Research Centre, WC1N 3JH London, UK., Achermann JC; UCL Great Ormond Street Institute of Child Health, WC1N 1EH London, UK., Haniffa M; Wellcome Sanger Institute, CB10 1SA Hinxton, UK.; Institute of Cellular Medicine, Newcastle University, NE2 4HH Newcastle upon Tyne, UK.; Department of Dermatology and NIHR Newcastle Biomedical Research Centre, Newcastle Hospitals, NHS Foundation Trust, NE2 4LP Newcastle upon Tyne, UK., Teichmann SA; Wellcome Sanger Institute, CB10 1SA Hinxton, UK., Rampling D; Great Ormond Street Hospital for Children (GOSH), NHS Foundation Trust, NIHR Great Ormond Street Hospital Biomedical Research Centre, WC1N 3JH London, UK., Sebire NJ; Great Ormond Street Hospital for Children (GOSH), NHS Foundation Trust, NIHR Great Ormond Street Hospital Biomedical Research Centre, WC1N 3JH London, UK., He X; MRC-WT Cambridge Stem Cell Institute, University of Cambridge, CB2 0QQ Cambridge, UK.; Department of Clinical Neurosciences, University of Cambridge, CB2 0QQ Cambridge, UK., de Krijger RR; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, Netherlands.; Department of Pathology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, Netherlands., Barker RA; MRC-WT Cambridge Stem Cell Institute, University of Cambridge, CB2 0QQ Cambridge, UK.; Department of Clinical Neurosciences, University of Cambridge, CB2 0QQ Cambridge, UK., Meyer KB; Wellcome Sanger Institute, CB10 1SA Hinxton, UK., Bayraktar O; Wellcome Sanger Institute, CB10 1SA Hinxton, UK., Straathof K; UCL Great Ormond Street Institute of Child Health, WC1N 1EH London, UK. my4@sanger.ac.uk k.straathof@ucl.ac.uk j.j.molenaar@prinsesmaximacentrum.nl sb31@sanger.ac.uk.; Great Ormond Street Hospital for Children (GOSH), NHS Foundation Trust, NIHR Great Ormond Street Hospital Biomedical Research Centre, WC1N 3JH London, UK., Molenaar JJ; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, Netherlands. my4@sanger.ac.uk k.straathof@ucl.ac.uk j.j.molenaar@prinsesmaximacentrum.nl sb31@sanger.ac.uk., Behjati S; Wellcome Sanger Institute, CB10 1SA Hinxton, UK. my4@sanger.ac.uk k.straathof@ucl.ac.uk j.j.molenaar@prinsesmaximacentrum.nl sb31@sanger.ac.uk.; Cambridge University Hospitals NHS Foundation Trust, CB2 0QQ Cambridge, UK.; Department of Paediatrics, University of Cambridge, CB2 0QQ Cambridge, UK.

Publikováno v: Science advances [Sci Adv] 2021 Feb 05; Vol. 7 (6). Date of Electronic Publication: 2021 Feb 05 (Print Publication: 2021).

TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets.

Autor: Decaesteker B; Center for Medical Genetics, Ghent University, Ghent, 9000, Belgium. bieke.decaesteker@ugent.be.; Cancer Research Institute Ghent (CRIG), Ghent, 9000, Belgium. bieke.decaesteker@ugent.be., Denecker G; Center for Medical Genetics, Ghent University, Ghent, 9000, Belgium.; Cancer Research Institute Ghent (CRIG), Ghent, 9000, Belgium., Van Neste C; Center for Medical Genetics, Ghent University, Ghent, 9000, Belgium.; Cancer Research Institute Ghent (CRIG), Ghent, 9000, Belgium., Dolman EM; Princess Máxima Center for Pediatric Oncology, Department of Translational Research, Utrecht, 3584, The Netherlands., Van Loocke W; Center for Medical Genetics, Ghent University, Ghent, 9000, Belgium.; Cancer Research Institute Ghent (CRIG), Ghent, 9000, Belgium., Gartlgruber M; Neuroblastoma Genomics, German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany., Nunes C; Center for Medical Genetics, Ghent University, Ghent, 9000, Belgium.; Cancer Research Institute Ghent (CRIG), Ghent, 9000, Belgium., De Vloed F; Center for Medical Genetics, Ghent University, Ghent, 9000, Belgium.; Cancer Research Institute Ghent (CRIG), Ghent, 9000, Belgium., Depuydt P; Center for Medical Genetics, Ghent University, Ghent, 9000, Belgium.; Cancer Research Institute Ghent (CRIG), Ghent, 9000, Belgium., Verboom K; Center for Medical Genetics, Ghent University, Ghent, 9000, Belgium.; Cancer Research Institute Ghent (CRIG), Ghent, 9000, Belgium., Rombaut D; Center for Medical Genetics, Ghent University, Ghent, 9000, Belgium.; Cancer Research Institute Ghent (CRIG), Ghent, 9000, Belgium., Loontiens S; Center for Medical Genetics, Ghent University, Ghent, 9000, Belgium.; Cancer Research Institute Ghent (CRIG), Ghent, 9000, Belgium., De Wyn J; Center for Medical Genetics, Ghent University, Ghent, 9000, Belgium.; Cancer Research Institute Ghent (CRIG), Ghent, 9000, Belgium., Kholosy WM; Princess Máxima Center for Pediatric Oncology, Department of Translational Research, Utrecht, 3584, The Netherlands., Koopmans B; Princess Máxima Center for Pediatric Oncology, Department of Translational Research, Utrecht, 3584, The Netherlands., Essing AHW; Princess Máxima Center for Pediatric Oncology, Department of Translational Research, Utrecht, 3584, The Netherlands., Herrmann C; Institute of Pharmacy and Molecular Biotechnology, and Bioquant Center, University of Heidelberg, Im Neuenheimer Feld 267, Heidelberg, 69120, Germany.; Division of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, 69120, Germany., Dreidax D; Neuroblastoma Genomics, German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany., Durinck K; Center for Medical Genetics, Ghent University, Ghent, 9000, Belgium.; Cancer Research Institute Ghent (CRIG), Ghent, 9000, Belgium., Deforce D; Cancer Research Institute Ghent (CRIG), Ghent, 9000, Belgium.; Laboratory of Pharmaceutical Biotechnology, Ghent University, Ghent, 9000, Belgium., Van Nieuwerburgh F; Cancer Research Institute Ghent (CRIG), Ghent, 9000, Belgium.; Laboratory of Pharmaceutical Biotechnology, Ghent University, Ghent, 9000, Belgium., Henssen A; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin, 13353, Germany.; German Cancer Consortium (DKTK), Heidelberg, 69120, Germany.; Berlin Institute of Health, Berlin, 13353, Germany., Versteeg R; Department of Oncogenomics, Academic Medical Center, Amsterdam, 1105, AZ, Netherlands., Boeva V; Institut Cochin, INSERM U1016, CNRS UMR 8104, Paris Descartes University UMR-S1016, Paris, 75014, France., Schleiermacher G; Institut Curie, PSL Research University, Equipe Labellisée Ligue contre le Cancer, Laboratory Recherche Translationnelle en Oncologie Pédiatrique (RTOP), Laboratoire 'Gilles Thomas', Institut Curie, Department of Translational Research, Institut Curie, SIREDO: Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, Paris, 75248, France., van Nes J; Department of Oncogenomics, Academic Medical Center, Amsterdam, 1105, AZ, Netherlands., Mestdagh P; Center for Medical Genetics, Ghent University, Ghent, 9000, Belgium.; Cancer Research Institute Ghent (CRIG), Ghent, 9000, Belgium., Vanhauwaert S; Center for Medical Genetics, Ghent University, Ghent, 9000, Belgium.; Cancer Research Institute Ghent (CRIG), Ghent, 9000, Belgium., Schulte JH; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin, 13353, Germany., Westermann F; Neuroblastoma Genomics, German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany., Molenaar JJ; Princess Máxima Center for Pediatric Oncology, Department of Translational Research, Utrecht, 3584, The Netherlands., De Preter K; Center for Medical Genetics, Ghent University, Ghent, 9000, Belgium.; Cancer Research Institute Ghent (CRIG), Ghent, 9000, Belgium., Speleman F; Center for Medical Genetics, Ghent University, Ghent, 9000, Belgium. Franki.speleman@ugent.be.; Cancer Research Institute Ghent (CRIG), Ghent, 9000, Belgium. Franki.speleman@ugent.be.

Publikováno v: Nature communications [Nat Commun] 2018 Nov 19; Vol. 9 (1), pp. 4866. Date of Electronic Publication: 2018 Nov 19.